Biocon, an innovation‑led global biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) has approved Pebrilzo (pertuzumab-qcay), a biosimilar of the reference product Perjeta (pertuzumab). PEBRILZO is a monoclonal antibody used to treat HER2-positive breast cancer by blocking HER2 receptors on cancer cells. The FDA approval further strengthens Biocon’s oncology portfolio.
Shreehas Tambe, CEO & Managing Director, Biocon said, “The US FDA approval of PEBRILZO, our biosimilar pertuzumab, marks another significant milestone in Biocon’s journey to expand access to high-quality biosimilars. For patients diagnosed with HER2-positive breast cancer, the burden of the disease extends well beyond the physical challenges, often placing considerable financial strain on patients and their families. As our fifth oncology biosimilar to receive U.S. FDA approval, PEBRILZO strengthens our anti-cancer portfolio and advances our commitment to expanding access to high-quality, affordable biologic medicines.”
In September, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had given a positive opinion recommending the granting of a marketing authorization for Biocon’s Pertuzumab biosimilar as 420 mg/14 mL concentrate solution for infusion, under the brand name Pebrilzo, for the treatment of HER2‑positive breast cancer across multiple disease stages in Europe.
Biocon also announced a global settlement and license agreement with Genentech securing the earliest licensed launch date for PEBRILZO in the United States in Q3 of calendar year 2028.